CRISPR Therapeutics (CRSP) Prices 4M Common Stock IPO at $14/Share, Below Prior Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
CRISPR Therapeutics Announces Pricing of Initial Public Offering
October 18, 2016 10:00 PM EDTBASEL, Switzerland and CAMBRIDGE, Mass., Oct. 18, 2016 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines, today announced the pricing of its initial public offering of 4,000,000 common shares at a public offering price of $14.00 per share. In addition, CRISPR Therapeutics has granted the underwriters a 30-day option to purchase up to 600,000 additional common shares at the initial public offering price, less the underwriting discounts and commissions. CRISPR Therapeutics common shares are expected to begin trading on the NASDAQ Global Market under the ticker symbol CRSP... More
